Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Molecular MRD status and outcome after transplantation in NPM1-mutated AML.
Dillon R, Hills R, Freeman S, Potter N, Jovanovic J, Ivey A, Kanda AS, Runglall M, Foot N, Valganon M, Khwaja A, Cavenagh J, Smith M, Ommen HB, Overgaard UM, Dennis M, Knapper S, Kaur H, Taussig D, Mehta P, Raj K, Novitzky-Basso I, Nikolousis E, Danby R, Krishnamurthy P, Hill K, Finnegan D, Alimam S, Hurst E, Johnson P, Khan A, Salim R, Craddock C, Spearing R, Gilkes A, Gale R, Burnett A, Russell NH, Grimwade D. Dillon R, et al. Among authors: nikolousis e. Blood. 2020 Feb 27;135(9):680-688. doi: 10.1182/blood.2019002959. Blood. 2020. PMID: 31932839 Free PMC article. Clinical Trial.
Factors predicting long-term survival after T-cell depleted reduced intensity allogeneic stem cell transplantation for acute myeloid leukemia.
Craddock C, Nagra S, Peniket A, Brookes C, Buckley L, Nikolousis E, Duncan N, Tauro S, Yin J, Liakopoulou E, Kottaridis P, Snowden J, Milligan D, Cook G, Tholouli E, Littlewood T, Peggs K, Vyas P, Clark F, Cook M, Mackinnon S, Russell N. Craddock C, et al. Among authors: nikolousis e. Haematologica. 2010 Jun;95(6):989-95. doi: 10.3324/haematol.2009.013920. Epub 2009 Nov 30. Haematologica. 2010. PMID: 19951968 Free PMC article.
Impact of pre-transplant co-morbidities on outcome after alemtuzumab-based reduced intensity conditioning allo-SCT in elderly patients: a British Society of Blood and Marrow Transplantation study.
Nikolousis E, Nagra S, Pearce R, Perry J, Kirkland K, Byrne J, Dignan F, Tholouli E, Gilleece M, Russell N, Littlewood T, Cook M, Peniket A, Shaw BE, Cook G, Craddock C. Nikolousis E, et al. Bone Marrow Transplant. 2015 Jan;50(1):82-6. doi: 10.1038/bmt.2014.215. Epub 2014 Oct 6. Bone Marrow Transplant. 2015. PMID: 25285801
Very early lineage-specific chimerism after reduced intensity stem cell transplantation is highly predictive of clinical outcome for patients with myeloid disease.
Kinsella FAM, Inman CF, Gudger A, Chan YT, Murray DJ, Zuo J, McIlroy G, Nagra S, Nunnick J, Holder K, Wall K, Griffiths M, Craddock C, Nikolousis E, Moss P, Malladi R. Kinsella FAM, et al. Among authors: nikolousis e. Leuk Res. 2019 Aug;83:106173. doi: 10.1016/j.leukres.2019.106173. Epub 2019 Jun 18. Leuk Res. 2019. PMID: 31276965
Graft-versus-leukaemia effect post fludarabine, melphalan and alemtuzumab reduced intensity allogeneic stem cell transplantat in HIV-infected patient with acute myeloid leukaemia.
Kanellopoulos A, Kaparou M, Xenou E, Paneesha S, Kishore B, Lovell R, Holder K, Suhr J, Baker L, Ryan L, Nikolousis E. Kanellopoulos A, et al. Among authors: nikolousis e. Bone Marrow Transplant. 2018 Dec;53(12):1518-1521. doi: 10.1038/s41409-018-0297-z. Epub 2018 Aug 16. Bone Marrow Transplant. 2018. PMID: 30116019
Reduced intensity alemtuzumab-containing allogeneic stem cell transplantation for relapsed/refractory low grade lymphoma: reflections on a single center experience.
Horgan C, Elmoamly S, McIlroy G, Davies D, Kaparou M, Giles H, Xenou E, Kishore B, Lovell R, Nikolousis E, Shankara P, Kanellopoulos A. Horgan C, et al. Among authors: nikolousis e. Leuk Lymphoma. 2019 Dec;60(12):3075-3077. doi: 10.1080/10428194.2019.1607323. Epub 2019 May 13. Leuk Lymphoma. 2019. PMID: 31079514 No abstract available.
Post-transplant T cell chimerism predicts graft versus host disease but not disease relapse in patients undergoing an alemtuzumab based reduced intensity conditioned allogeneic transplant.
Nikolousis E, Robinson S, Nagra S, Brookes C, Kinsella F, Tauro S, Jeffries S, Griffiths M, Mahendra P, Cook M, Paneesha S, Lovell R, Kishore B, Chaganti S, Malladi R, Raghavan M, Moss P, Milligan D, Craddock C. Nikolousis E, et al. Leuk Res. 2013 May;37(5):561-5. doi: 10.1016/j.leukres.2013.01.010. Epub 2013 Feb 5. Leuk Res. 2013. PMID: 23395505 Clinical Trial.
39 results